337 related articles for article (PubMed ID: 20932292)
21. Aberrations of ERBB2 and TOP2A genes in breast cancer.
Nielsen KV; Müller S; Møller S; Schønau A; Balslev E; Knoop AS; Ejlertsen B
Mol Oncol; 2010 Apr; 4(2):161-8. PubMed ID: 19945923
[TBL] [Abstract][Full Text] [Related]
22. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
[TBL] [Abstract][Full Text] [Related]
23. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer.
Zhang EY; Cristofanilli M; Robertson F; Reuben JM; Mu Z; Beavis RC; Im H; Snyder M; Hofree M; Ideker T; Omenn GS; Fanayan S; Jeong SK; Paik YK; Zhang AF; Wu SL; Hancock WS
J Proteome Res; 2013 Jun; 12(6):2805-17. PubMed ID: 23647160
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
25. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M; Dowhan DH
Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
[TBL] [Abstract][Full Text] [Related]
26. A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.
Marotta M; Chen X; Inoshita A; Stephens R; Budd GT; Crowe JP; Lyons J; Kondratova A; Tubbs R; Tanaka H
Breast Cancer Res; 2012 Nov; 14(6):R150. PubMed ID: 23181561
[TBL] [Abstract][Full Text] [Related]
27. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
28. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Kauraniemi P; Kallioniemi A
Endocr Relat Cancer; 2006 Mar; 13(1):39-49. PubMed ID: 16601278
[TBL] [Abstract][Full Text] [Related]
29. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes.
Kao J; Pollack JR
Genes Chromosomes Cancer; 2006 Aug; 45(8):761-9. PubMed ID: 16708353
[TBL] [Abstract][Full Text] [Related]
30. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
31. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
[TBL] [Abstract][Full Text] [Related]
32. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
[TBL] [Abstract][Full Text] [Related]
33. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.
Zito CI; Riches D; Kolmakova J; Simons J; Egholm M; Stern DF
Genes Chromosomes Cancer; 2008 Jul; 47(7):633-8. PubMed ID: 18418848
[TBL] [Abstract][Full Text] [Related]
34. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.
Morrison LE; Jewell SS; Usha L; Blondin BA; Rao RD; Tabesh B; Kemper M; Batus M; Coon JS
Genes Chromosomes Cancer; 2007 Apr; 46(4):397-405. PubMed ID: 17243161
[TBL] [Abstract][Full Text] [Related]
35. Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes.
Myllykangas S; Junnila S; Kokkola A; Autio R; Scheinin I; Kiviluoto T; Karjalainen-Lindsberg ML; Hollmén J; Knuutila S; Puolakkainen P; Monni O
Int J Cancer; 2008 Aug; 123(4):817-25. PubMed ID: 18506690
[TBL] [Abstract][Full Text] [Related]
36. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.
Yao J; Weremowicz S; Feng B; Gentleman RC; Marks JR; Gelman R; Brennan C; Polyak K
Cancer Res; 2006 Apr; 66(8):4065-78. PubMed ID: 16618726
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.
Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V
Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995
[TBL] [Abstract][Full Text] [Related]
38. How basal are triple-negative breast cancers?
Bertucci F; Finetti P; Cervera N; Esterni B; Hermitte F; Viens P; Birnbaum D
Int J Cancer; 2008 Jul; 123(1):236-40. PubMed ID: 18398844
[TBL] [Abstract][Full Text] [Related]
39. Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
Manzano RG; Martinez-Navarro EM; Forteza J; Brugarolas A
Int J Oncol; 2014 Dec; 45(6):2250-66. PubMed ID: 25201346
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
